Olink®Part of Thermo Fisher Scientific
Powerful, NGS-based proteomics - effortlessly uncover meaningful insights
A unique combination of specificity and scalability enables high-throughput, multiplex protein biomarker analysis.
Next-generation high-throughput proteomics empowers genetically-informed assessment of protein causality and the confident identification of novel drug targets.
Join the growing global community and consortia of Olink users to empower your biomarker discovery.
Over 3,400 and growing rapidly – covering all major disease areas
Your source for Olink’s terms, privacy policies, and compliance details
Filters
Frontiers in Immunology, 2023Therapeutic role of interleukin-1 receptor antagonist in pancreatic diseases: mendelian randomization study
Yuan S., Miao Y., Ruan X. et al.
Olink Target 96
Nature Communications, 2023CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease
del Campo M., Vermunt L., Peeters C. et al.
Olink Focus
mSystems, 2023Abnormal blood microbiota profiles are associated with inflammation and immune restoration in HIV/AIDS individuals
Guo X., Wang Z., Qu M. et al.
Open Forum Infectious Diseases, 2023Biological and Clinical Implications of the Vascular Endothelial Growth Factor Coreceptor Neuropilin-1 in Human Immunodeficiency Virus
Schnittman S., Kolossváry M., Beck-Engeser G. et al.
Nature Communications, 2023Impact of dietary interventions on pre-diabetic oral and gut microbiome, metabolites and cytokines
Shoer S., Shilo S., Godneva A. et al.
Nature Communications, 2023Interpreting biologically informed neural networks for enhanced proteomic biomarker discovery and pathway analysis
Hartman E., Scott A., Karlsson C. et al.
Thrombosis Research, 2023Plasma protein signatures for high on-treatment platelet reactivity to aspirin and clopidogrel in peripheral artery disease
Baidildinova G., Pallares Robles A., ten Cate V. et al.
Cell Reports Medicine, 2023Plasma proteins and onset of type 2 diabetes and diabetic complications: Proteome-wide Mendelian randomization and colocalization analyses
Yuan S., Xu F., Li X. et al.
Olink Explore 3072/384
Vascular Pharmacology, 2023Circulating soluble IL-6 receptor associates with plaque inflammation but not with atherosclerosis severity and cardiovascular risk
Edsfeldt A., Gonçalves I., Vigren I. et al.
Liver International, 2023Binge drinking episode causes acute, specific alterations in systemic and hepatic inflammation‐related markers
Stankevic E., Israelsen M., Juel H. et al.
Journal of Endocrinological Investigation, 2023Serum biomarkers related to frailty predict negative outcomes in older adults with hip fracture
Cedeno-Veloz B., Lozano-Vicario L., Rodríguez-García A. et al.
Olink Target 48
Nature Communications, 2023Genetic analysis of blood molecular phenotypes reveals common properties in the regulatory networks affecting complex traits
Brown A., Fernandez-Tajes J., Hong M. et al.
Aging Cell, 2023Peripheral inflammatory biomarkers are associated with cognitive function and dementia: Framingham Heart Study Offspring cohort
Chen J., Doyle M., Fang Y. et al.
Nature Immunology, 2023Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets
Zhao J., Stacey D., Eriksson N. et al.
Environmental Science & Technology, 2023Effects of Short- And Medium-Term Exposures to Lower Air Temperature on 71 Novel Biomarkers of Subclinical Inflammation: Results from the KORA F4 Study
Ni W., Breitner S., Nikolaou N. et al.
Allergy, 2023Dupilumab‐induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis
Ryser F., Yalamanoglu A., Valaperti A. et al.
European Journal of Immunology, 2023Proteomics reveals a global phenotypic shift of NK cells in HCV patients treated with direct‐acting antivirals
Bi W., Kraft A., Engelskircher S. et al.
JAMA Network Open, 2023Biomarkers Associated With Severe COVID-19 Among Populations With High Cardiometabolic Risk
Sood T., Perrot N., Chong M. et al.
Hematological Oncology, 2023Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL‐102): A phase 1 study
Hamadani M., Coleman M., Boccia R. et al.
eBioMedicine, 2023Plasma proteomic profiling identifies CD33 as a marker of HIV control in natural infection and after therapeutic vaccination
Duran-Castells C., Prats A., Oriol-Tordera B. et al.
3478 publications
Items per page
481-500 of 3478 publications